Australia markets closed

Silo Pharma, Inc. (SILO)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.1850+0.0046 (+2.58%)
At close: 3:58PM EDT
Full screen
Loading interactive chart…
  • GlobeNewswire

    Silo Pharma Advances Psychedelic Patent Portfolio

    Englewood Cliffs NJ, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced the filing of three distinct Patent Cooperation Treaty (PCT) patent applications pertaining to the central nervous system delivery of unique anti-inflammatory therapeutics coupled with psilocybin. “Each of these PCT applications relates to the continued research and development that Silo Pharma h

  • GlobeNewswire

    Silo Pharma Announces that JV partner Zylo Therapeutics Successfully Completes Initial Inspection for Ketamine Intradermal Research

    Englewood Cliffs NJ, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB:SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that Silo’s joint venture partner, ZYLO Therapeutics, completed its first inspection with the SC Board of Pharmacy and will move forward with the Department of Health and Environmental Control. Eric Weisblum, CEO of Silo Pharma stated “Completion of the first inspection is an important step forwar

  • GlobeNewswire

    Silo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide Patent

    Central Nervous System Homing Peptide under development to deliver Psychedelics including Psilocybin Englewood Cliffs NJ, July 27, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB:SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announcedthat the United States Patent Office has issued a notice of allowance for a patent application related to the Company's Central Nervous System Homing Peptide. "We are pleased to have been granted th